Search

everythinglearnresearchcommunity

for

Search:↓

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

Mixed Connective Tissue Disease can develop from overlapping symptoms of several autoimmune diseases, making diagnosis complex.

DHT inhibition may increase spinal bone growth in ankylosing spondylitis.

Alopecia areata involves specific T-cells, unlike androgenetic alopecia.

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

Stress hormones like cortisol may trigger psoriasis flare-ups.

JAK inhibitors are recommended for severe alopecia areata if corticosteroids fail.

DHEA therapy improves pubic hair growth and psychological well-being in girls with central adrenal insufficiency.

A rare autoimmune condition, Satoyoshi syndrome, can start in adults and improve with immunosuppressive treatment.

Systemic corticosteroids might help treat hair loss caused by alemtuzumab in MS patients.

Apremilast may help treat hair loss in alopecia areata.

The antibody created from BCC tissues reacts similarly to both BCC and hair follicles, suggesting BCC may come from hair follicle cells.

Tacrolimus and corticosteroids can improve symptoms of Satoyoshi syndrome.

Certain proteins are found at higher levels in balding areas compared to non-balding areas, suggesting a link to hair loss. This could be useful for diagnosing and treating hair loss.

Myeloid-derived suppressor cells help control autoimmune cells and promote hair regrowth in alopecia areata.

Women with PCOS have higher 5alpha-reductase activity, affecting steroid levels.

Inflammation may play a role in causing androgenetic alopecia.

CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss.

Men might have a version of the female disease, polycystic ovarian syndrome, shown by changes in hormone levels and early baldness, but more research is needed to fully understand it.

A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.

iNKT cells can help prevent and treat alopecia areata by promoting hair regrowth.

Dermal IgA deposition without symptoms is rare in Dermatitis herpetiformis risk groups.

Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.

Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.

ANA-negative lupus nephritis can be diagnosed and treated effectively with a comprehensive approach.